Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026
Globe Newswire•20/11/2026•16:01 ET
1
Key Highlights
- ➤November 23, 2026: Kymera will announce BROADEN2 Phase 2b atopic dermatitis results
- ➤7:00 a.m. ET: Kymera will issue the KT-621 trial-results press release
- ➤8:00 a.m. ET: Kymera will host a video conference and webcast
- ➤KT-621 is an investigational once-daily oral STAT6 degrader in atopic dermatitis and asthma
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, November 23, 2026
WATERTOWN, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BROADEN2 Phase 2b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, November 23, 2026. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.
Get started
Create a free account to read the full story.
